FAQ: Branded Legacy's Air-Driven Intranasal Drug Delivery Platform Development

What is the main announcement from Branded Legacy, Inc.?

Branded Legacy announced that its subsidiary, BioLegacy Evaluative Group Inc., has begun engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform.

What is the purpose of this air-driven intranasal drug delivery platform?

The platform enables rapid, reliable therapeutic delivery through single-use devices, including the company’s flagship inhaled naloxone program designed to address the opioid crisis.

Why is this development significant?

This milestone advances scalable production of affordable, high-quality pharmaceutical solutions for addiction treatment and harm reduction, strengthening the company’s capacity to address the opioid crisis.

Who is involved in this development?

The development is being conducted by Branded Legacy’s subsidiary BioLegacy Evaluative Group Inc., with strategic collaborations with leading institutions like McMaster University and Stanford University.

Where is the manufacturing facility located?

Branded Legacy operates a state-of-the-art GMP-compliant manufacturing facility in Vancouver.

When was the provisional patent filed for this technology?

The company filed a provisional patent in September 2025 for its proprietary air-driven intranasal drug delivery platform.

What type of company is Branded Legacy, Inc.?

Branded Legacy is a forward-thinking holdings company (OTC: BLEG) dedicated to pioneering solutions in addiction treatment and harm reduction through its subsidiary BioLegacy Evaluative Group.

How does this development benefit public health?

It strengthens the company’s capacity to deliver affordable, high-quality pharmaceutical solutions for critical public health challenges, particularly the opioid crisis through rapid therapeutic delivery systems.

Where can I find more information about Branded Legacy?

For more information, visit the company’s website at https://BrandedLegacy.com or view the full press release at https://ibn.fm/Lgrhz.

What makes this drug delivery platform unique?

It is a proprietary air-driven intranasal delivery system designed as a single-use device for rapid, reliable therapeutic delivery, building on the company’s September 2025 provisional patent filing.